Nicole Bertoletti

Dr. Nicole Bertoletti

Yale University School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JIJoseph A. Ippolito
Joseph A. Ippolito
HNHaichan Niu
Haichan Niu
Nicole BertolettiNicole Bertoletti
Nicole Bertoletti
ZCZachary J. Carter
Zachary J. Carter
SJShengyan Jin
Shengyan Jin
WJWilliam L. Jorgensen
William L. Jorgensen

21 March 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SKStefan G. Krimmer
Stefan G. Krimmer
Nicole BertolettiNicole Bertoletti
Nicole Bertoletti
YSYoshihisa Suzuki
Yoshihisa Suzuki
LKLuka Katic
Luka Katic
JMJyotidarsini Mohanty
Jyotidarsini Mohanty
JSJoseph Schlessinger
Joseph Schlessinger
The receptor tyrosine kinase KIT and its ligand stem cell factor (SCF) are required for the development of hematopoietic stem cells, germ cells, and other cells. A variety of human cancers, such as acute myeloid leukemia, gastrointestinal stromal tumor, and mast cell leukemia, are driven by somatic gain-of-function KIT mutations. Here, we report cryo electron microscopy (cryo-EM) structural analyses of full-length wild-type and two oncogenic KIT mutants, which show that the overall symmetric arrangement of the extracellular domain of ligand-occupied KIT dimers contains asymmetric D5 homotypic contacts juxtaposing the plasma membrane. Mutational analysis of KIT reveals in D5 region an “Achilles heel” for therapeutic intervention. A ligand-sensitized oncogenic KIT mutant exhibits a more comprehensive and stable D5 asymmetric conformation. A constitutively active ligand-independent oncogenic KIT mutant adopts a V-shaped conformation solely held by D5-mediated contacts. Binding of SCF to this mutant fully restores the conformation of wild-type KIT dimers, including the formation of salt bridges responsible for D4 homotypic contacts and other hallmarks of SCF-induced KIT dimerization. These experiments reveal an unexpected structural plasticity of oncogenic KIT mutants and a therapeutic target in D5.

13 July 2019 in Protein Science
Verified
Journal Article
Open access
PDF file
Nicole BertolettiNicole Bertoletti
Nicole Bertoletti
ACAlbert H. Chan
Albert H. Chan
RSRaymond F. Schinazi
Raymond F. Schinazi
YYY. Whitney Yin
Y. Whitney Yin
KAKaren Anderson
Karen Anderson
The retrovirus HIV‐1 has been a major health issue since its discovery in the early 80s. In 2017, over 37 million people were infected with HIV‐1, of which 1.8 million were new infections that year. Currently, the most successful treatment regimen is the highly active antiretroviral therapy (HAART), which consists of a combination of three to four of the current 26 FDA‐approved HIV‐1 drugs. Half of these drugs target the reverse transcriptase (RT) enzyme that is essential for viral replication. One class of RT inhibitors is nucleoside reverse transcriptase inhibitors (NRTIs), a crucial component of the HAART. Once incorporated into DNA, NRTIs function as a chain terminator to stop viral DNA replication. Unfortunately, treatment with NRTIs is sometimes linked to toxicity caused by off‐target side effects. NRTIs may also target the replicative human mitochondrial DNA polymerase (Pol γ), causing long‐term severe drug toxicity. The goal of this work is to understand the discrimination mechanism of different NRTI analogues by RT. Crystal structures and kinetic experiments are essential for the rational design of new molecules that are able to bind selectively to RT and not Pol γ. Structural comparison of NRTI‐binding modes with both RT and Pol γ enzymes highlights key amino acids that are responsible for the difference in affinity of these drugs to their targets. Therefore, the long‐term goal of this research is to develop safer, next generation therapeutics that can overcome off‐target toxicity.

7 February 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ANAna S. Newton
Ana S. Newton
JFJohn C. Faver
John C. Faver
GMGoran Micevic
Goran Micevic
VMViswanathan Muthusamy
Viswanathan Muthusamy
SKShalley N. Kudalkar
Shalley N. Kudalkar
WJWilliam L. Jorgensen
William L. Jorgensen

1 July 2019 in Antiviral Research
Verified
Journal Article
Closed access
SKShalley N. Kudalkar
Shalley N. Kudalkar
IUIrfan Ullah
Irfan Ullah
Nicole BertolettiNicole Bertoletti
Nicole Bertoletti
HMHanna K. Mandl
Hanna K. Mandl
JCJosé A. Cisneros
José A. Cisneros
KAKaren Anderson
Karen Anderson

12 July 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Nicole BertolettiNicole Bertoletti
Nicole Bertoletti
FBFlorian Braun
Florian Braun
MLMahalia Lepage
Mahalia Lepage
GMGabriele Möller
Gabriele Möller
Jerzy AdamskiJerzy Adamski
Jerzy Adamski
SMSandrine Marchais-Oberwinkler
Sandrine Marchais-Oberwinkler